Cingulate Inc (CING)

$6.49 +0.24 (3.84%)
Market Cap 46.54M
Revenue (ttm) 0.00
Net Income (ttm) -15.55M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 918,500
Avg Vol 231,726
Day's Range N/A - N/A
Shares Out 7.45M
Stochastic %K 63%
Beta -0.75
Analysts Strong Sell
Price Target $27.40

Company Profile

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1...

Industry: Biotechnology
Sector: Healthcare
Phone: 913 942 2300
Address:
1901 West 47th Place, Kansas City, United States
PhiloftheFuture
PhiloftheFuture Feb. 6 at 4:26 PM
$CING not trending is the story here
0 · Reply
Raretype
Raretype Feb. 6 at 4:25 PM
$CING people are reacting to the market which is taking a dump. CING is green and top tier of a tiny handful of upward movers, so many are jumping on the only green bandwagon in town. I expect huge profit taking as soon as this afternoon and low 6’s again by midweek. Don’t get me wrong though, this stock has a long run bright future!
0 · Reply
meeru
meeru Feb. 6 at 4:22 PM
$CING CALL UR BROKER AND GET THEM TO ADD OPTIONS ON THIS THING!!!!!!!!!!!!
1 · Reply
The_Baba_Yaga
The_Baba_Yaga Feb. 6 at 4:16 PM
$CING
0 · Reply
MOOSEN
MOOSEN Feb. 6 at 4:16 PM
$SLS GOT SOME $CING SCALPS ROLLING IN.
1 · Reply
MichaelDV
MichaelDV Feb. 6 at 4:13 PM
$CING microcap drifting quietly, float driven upside if volume appears
0 · Reply
TheSuper
TheSuper Feb. 6 at 4:03 PM
$CING Even at $7.50 this is a steal -> Patent news catalyst -> PUFDA catalyst -> 6 months out sales -> triple digits easy. Top plays: $SLS $CING $PYPD $OCGN Lotto pick: $GOSS May 15th $3 calls.
1 · Reply
geothug
geothug Feb. 6 at 3:56 PM
$CING 👀 definitely feeling the FOMO.
1 · Reply
CashNotKing
CashNotKing Feb. 6 at 3:55 PM
$CING How high? 🤔
0 · Reply
MOOSEN
MOOSEN Feb. 6 at 3:47 PM
$SLS $CING HOT.
0 · Reply
Latest News on CING
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25

Nov 18, 2025, 4:27 PM EST - 2 months ago

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25

Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

Oct 23, 2025, 4:45 PM EDT - 3 months ago

Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting

Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment

Sep 17, 2025, 8:45 AM EDT - 5 months ago

Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25

Aug 21, 2025, 4:35 PM EDT - 6 months ago

Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25

Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

Aug 19, 2025, 8:45 AM EDT - 6 months ago

Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights

Cingulate Provides Management Team Update

Aug 15, 2025, 9:00 AM EDT - 6 months ago

Cingulate Provides Management Team Update

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Aug 6, 2025, 8:45 AM EDT - 6 months ago

Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301

Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING)

Jun 18, 2025, 8:00 AM EDT - 8 months ago

Stonegate Capital Partners Initiates Coverage on Cingulate Inc. (CING)

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

May 8, 2025, 4:30 PM EDT - 9 months ago

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

Apr 9, 2025, 8:00 AM EDT - 10 months ago

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

Mar 26, 2025, 5:00 PM EDT - 11 months ago

Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

Dec 23, 2024, 7:30 AM EST - 1 year ago

Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000

Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

Nov 7, 2024, 7:30 AM EST - 1 year ago

Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

Oct 8, 2024, 3:15 PM EDT - 1 year ago

Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

Sep 12, 2024, 8:30 AM EDT - 1 year ago

Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

Cingulate to Participate in Benzinga All Live Access Event

Aug 27, 2024, 4:30 PM EDT - 1 year ago

Cingulate to Participate in Benzinga All Live Access Event

Cingulate Announces Adjournment of Special Meeting

Aug 23, 2024, 4:45 PM EDT - 1 year ago

Cingulate Announces Adjournment of Special Meeting

Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy?

Aug 16, 2024, 12:36 PM EDT - 1 year ago

Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy?

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

Aug 15, 2024, 7:45 AM EDT - 1 year ago

Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD

Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

Aug 13, 2024, 7:45 AM EDT - 1 year ago

Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds

Jun 28, 2024, 9:15 AM EDT - 1 year ago

Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds

Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

Jun 25, 2024, 4:30 PM EDT - 1 year ago

Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event

Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance

Jun 25, 2024, 9:20 AM EDT - 1 year ago

Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance

Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

May 8, 2024, 7:00 AM EDT - 1 year ago

Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access

Apr 30, 2024, 5:45 AM EDT - 1 year ago

Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access

Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024

Apr 16, 2024, 5:00 PM EDT - 1 year ago

Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

Apr 1, 2024, 8:00 AM EDT - 2 years ago

Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update

Cingulate to Attend DCAT Week 2024 in New York City

Mar 6, 2024, 6:45 AM EST - 2 years ago

Cingulate to Attend DCAT Week 2024 in New York City

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

Feb 13, 2024, 6:45 AM EST - 2 years ago

Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

Cingulate Announces Closing of $7.5 Million Public Offering

Feb 6, 2024, 4:15 PM EST - 2 years ago

Cingulate Announces Closing of $7.5 Million Public Offering

Cingulate Announces Pricing of $7.5 Million Public Offering

Feb 2, 2024, 9:15 AM EST - 2 years ago

Cingulate Announces Pricing of $7.5 Million Public Offering

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

Jan 29, 2024, 8:00 AM EST - 2 years ago

Longtime Cingulate Controller Jennifer Callahan Promoted to CFO

Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market

Jan 29, 2024, 6:45 AM EST - 2 years ago

Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market

Cingulate's stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearing

Dec 28, 2023, 7:19 AM EST - 2 years ago

Cingulate's stock skyrockets again, as ADHD treatment developer as delisting is delayed pending a February hearing

Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)

Dec 1, 2023, 9:00 AM EST - 2 years ago

Cingulate Receives Guidance from FDA on Path Forward for Anxiety Asset CTx-2103 (buspirone)

Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

Nov 13, 2023, 4:15 PM EST - 2 years ago

Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update

Cingulate to Host CNS Key Opinion Leader Panel in New York City

Oct 17, 2023, 2:22 PM EDT - 2 years ago

Cingulate to Host CNS Key Opinion Leader Panel in New York City

Cingulate Inc. to Present at the LD Micro Main Event XVI

Sep 21, 2023, 1:30 PM EDT - 2 years ago

Cingulate Inc. to Present at the LD Micro Main Event XVI

Cingulate Inc. To Present at the LD Micro Main Event XVI

Sep 21, 2023, 11:23 AM EDT - 2 years ago

Cingulate Inc. To Present at the LD Micro Main Event XVI

Cingulate Announces Closing of $4.0 Million Public Offering

Sep 13, 2023, 4:15 PM EDT - 2 years ago

Cingulate Announces Closing of $4.0 Million Public Offering

Cingulate Announces Pricing of $4.0 Million Public Offering

Sep 11, 2023, 9:22 AM EDT - 2 years ago

Cingulate Announces Pricing of $4.0 Million Public Offering

Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

Sep 11, 2023, 6:00 AM EDT - 2 years ago

Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium

Sep 8, 2023, 4:31 PM EDT - 2 years ago

Werth Family Investment Associates Converts $5.8 Million of Debt into Cingulate Equity at a Premium

Dr. Vince Clinical Research Announces First Dosing in Cingulate Therapeutics' CTx-1301 Phase III Laboratory Classroom Study in ADHD Patients

Sep 6, 2023, 9:00 AM EDT - 2 years ago

Dr. Vince Clinical Research Announces First Dosing in Cingulate Therapeutics' CTx-1301 Phase III Laboratory Classroom Study in ADHD Patients

Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023

Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update

Aug 14, 2023, 4:15 PM EDT - 2 years ago

Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update

Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August

Jun 29, 2023, 8:00 AM EDT - 2 years ago

Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August

Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest

Jun 14, 2023, 3:45 PM EDT - 2 years ago

Cingulate to Participate in the Healthcare Virtual Conference Part II Presented by Maxim Group and Hosted by M-Vest

Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD

Jun 8, 2023, 7:00 AM EDT - 2 years ago

Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD

Cingulate to Present at 13th Annual LD Micro Invitational

May 25, 2023, 3:55 PM EDT - 2 years ago

Cingulate to Present at 13th Annual LD Micro Invitational

PhiloftheFuture
PhiloftheFuture Feb. 6 at 4:26 PM
$CING not trending is the story here
0 · Reply
Raretype
Raretype Feb. 6 at 4:25 PM
$CING people are reacting to the market which is taking a dump. CING is green and top tier of a tiny handful of upward movers, so many are jumping on the only green bandwagon in town. I expect huge profit taking as soon as this afternoon and low 6’s again by midweek. Don’t get me wrong though, this stock has a long run bright future!
0 · Reply
meeru
meeru Feb. 6 at 4:22 PM
$CING CALL UR BROKER AND GET THEM TO ADD OPTIONS ON THIS THING!!!!!!!!!!!!
1 · Reply
The_Baba_Yaga
The_Baba_Yaga Feb. 6 at 4:16 PM
$CING
0 · Reply
MOOSEN
MOOSEN Feb. 6 at 4:16 PM
$SLS GOT SOME $CING SCALPS ROLLING IN.
1 · Reply
MichaelDV
MichaelDV Feb. 6 at 4:13 PM
$CING microcap drifting quietly, float driven upside if volume appears
0 · Reply
TheSuper
TheSuper Feb. 6 at 4:03 PM
$CING Even at $7.50 this is a steal -> Patent news catalyst -> PUFDA catalyst -> 6 months out sales -> triple digits easy. Top plays: $SLS $CING $PYPD $OCGN Lotto pick: $GOSS May 15th $3 calls.
1 · Reply
geothug
geothug Feb. 6 at 3:56 PM
$CING 👀 definitely feeling the FOMO.
1 · Reply
CashNotKing
CashNotKing Feb. 6 at 3:55 PM
$CING How high? 🤔
0 · Reply
MOOSEN
MOOSEN Feb. 6 at 3:47 PM
$SLS $CING HOT.
0 · Reply
The_Baba_Yaga
The_Baba_Yaga Feb. 6 at 3:40 PM
$CING
0 · Reply
MKRReformed
MKRReformed Feb. 6 at 3:34 PM
$CING has shown amazing strength given the market conditions the past week
0 · Reply
Jojo_Mojo12
Jojo_Mojo12 Feb. 6 at 3:34 PM
$CING wait I’m confused now. I thought the patent news about approval is end of May? What other news can they publish before that
1 · Reply
The_Baba_Yaga
The_Baba_Yaga Feb. 6 at 3:31 PM
$CING
0 · Reply
I_Buy_Stock
I_Buy_Stock Feb. 6 at 2:41 PM
$CING 33k shares here @ $5.23, was buying above $7 yesterday as well. Upside is huge with two catalysts before summer (US patent news and PDUFA)
0 · Reply
stockchacing
stockchacing Feb. 6 at 1:59 PM
$CING Looks today will be another day we will hit $7 and above. Expecting patent news somewhere between NOW and March.. then more catalysts to come... Extremly
0 · Reply
Boxcar66
Boxcar66 Feb. 6 at 12:31 PM
$CING Moring … Happy Friday ! Let’s go !!
0 · Reply
I_Buy_Stock
I_Buy_Stock Feb. 6 at 5:56 AM
$CING $SLS Just remember if you don't follow his politics in lockstep (radical left wing) he will ban you from any community he founds. He has no conviction at all. If one of his fellow left wingers thinks you are a nazi, that is all it takes. #byebye.
1 · Reply
StockScanners
StockScanners Feb. 6 at 5:46 AM
$CING keep watch if this holds above 6.36
1 · Reply
MOOSEN
MOOSEN Feb. 6 at 1:03 AM
$CING BOSSIN’.
0 · Reply
Rasto2020
Rasto2020 Feb. 6 at 12:58 AM
$CING it hit and some more .
0 · Reply
TheSuper
TheSuper Feb. 6 at 12:26 AM
$CING people can penny flip all they want here. I'll hold cash in big in near future.
0 · Reply